Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Purpose The aim of this study was to evaluate the therapeutic effects of Anamorelin on patients with cancer anorexia-cachexia syndrome (CACS) based on a meta-analysis of published randomized trials.Methods We searched PubMed, Embase, Medline, and the Cochrane Central Register of Controlled Trials databases. Data from each selected study were evaluated individually. All continuous outcomes were calculated by the mean difference or standardized mean difference with 95% confidence interval for each study. Heterogeneity was assessed by using the Chi 2 test at a significance level of P < 0.1, in addition to the I 2 statistic (I 2 > 50% indicated substantial heterogeneity).Result At last, four studies were included from 284 records. In three studies, lean body mass was reported and there was a significant difference between placebo and Anamorelin groups (P < 0.00001), without significant heterogeneity (I 2 = 0%). All the four studies reported the body weight change from baseline, and there was significant difference between placebo and Anamorelin groups (P = 0.007), but with high heterogeneity (I 2 = 97%). Two studies reported Anderson Symptom Assessment Scale (ASAS) score, and Anamorelin significantly increased the total ASAS score of CACS patients (P < 0.00001), without any heterogeneity (I 2 = 0%). Three studies reported non-dominant handgrip strength, and there was no significant difference between Anamorelin and placebo groups (P = 0.16). Three studies reported insulin-like growth factor-1 level, and there was significant difference between Anamorelin and placebo groups (P = 0.02), but with high heterogeneity (I 2 = 96%). Three studies reported IGF binding protein-3 concentration. Anamorelin significantly increased such concentration compared with placebo did (P < 0.00001). However, there was still higher heterogeneity (I 2 = 59%). All the included studies reported adverse events. Compared with placebo, Anamorelin induced fewer adverse events, but there was no significant difference between the two groups (RR = 0.07, P = 0.35).Conclusion In the included studies, Anamorelin had some positive effects to relieve the symptoms and improved the quality of life. However, the heterogeneity was apparent, so the clinical effects of Anamorelin should be further validated by increasing the sample size, varying the range of doses during treatment, and observing other outcomes. We are still confident for the future application of Anamorelin in phase III clinical trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A review of four studies demonstrated high heterogeneity with improved symptom scores, and in three studies, improved lean mass was shown439.”
From Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies (2018) · cites this paper as [439]
Citations
Cites
Definition and classification of cancer cachexia: an international consensus
Fearon, K., Strasser, F., Anker, S. D., Bosaeus, I., Bruera, E., Fainsinger, R. L., Jatoi, A., Loprinzi, C., MacDonald, N., Mantovani, G., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70218-7 · Cited by 5,767
Symptom Prevalence in Patients with Incurable Cancer: A Systematic Review
Teunissen, S. C. C. M., Wesker, W., Kruitwagen, C., de Haes, H. C. J. M., Voest, E. E., & de Graeff, A. (2007) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2006.10.015 · Cited by 990
Ghrelin Strongly Stimulates Growth Hormone Release in Humans
Takaya, K., Ariyasu, H., Kanamoto, N., Iwakura, H., Yoshimoto, A., Harada, M., Mori, K., Komatsu, Y., Usui, T., Shimatsu, A., et al. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.12.7167 · Cited by 864
Grip strength, body composition, and mortality
Gale, C. R., Martyn, C. N., Cooper, C., & Sayer, A. A. (2007) · International Journal of Epidemiology · doi:10.1093/ije/dyl224 · Cited by 737
Temel, J. S., Abernethy, A. P., Currow, D. C., Friend, J., Duus, E. M., Yan, Y., & Fearon, K. C. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00558-6 · Cited by 639
Cancer Anorexia-Cachexia Syndrome: Current Issues in Research and Management
Inui, A. (2002) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.52.2.72 · Cited by 579
Cachexia as a major underestimated and unmet medical need: facts and numbers
von Haehling, S., & Anker, S. D. (2010) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1007/s13539-010-0002-6 · Cited by 533
Inhibition of NF-κB Activity by Thalidomide through Suppression of IκB Kinase Activity
Keifer, J. A., Guttridge, D. C., Ashburner, B. P., & Jr.Baldwin, A. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100938200 · Cited by 478
Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?
Ross, P. J., Ashley, S., Norton, A., Priest, K., Waters, J. S., Eisen, T., Smith, I. E., & O'Brien, M. E. R. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601781 · Cited by 476
Aapro, M., Arends, J., Bozzetti, F., Fearon, K., Grunberg, S. M., Herrstedt, J., Hopkinson, J., Jacquelin-Ravel, N., Jatoi, A., Kaasa, S., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu085 · Cited by 308
Therapeutic Action of Ghrelin in a Mouse Model of Colitis
Gonzalez–Rey, E., Chorny, A., & Delgado, M. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.01.041 · Cited by 259
Garcia, J. M., Boccia, R. V., Graham, C. D., Yan, Y., Duus, E. M., Allen, S., & Friend, J. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71154-4 · Cited by 218
Ghrelin Attenuates Sepsis-induced Acute Lung Injury and Mortality in Rats
Wu, R., Dong, W., Zhou, M., Zhang, F., Marini, C. P., Ravikumar, T. S., & Wang, P. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200604-511oc · Cited by 204
DeBoer, M. D., Zhu, X. X., Levasseur, P., Meguid, M. M., Suzuki, S., Inui, A., Taylor, J. E., Halem, H. A., Dong, J. Z., Datta, R., et al. (2007) · Endocrinology · doi:10.1210/en.2007-0016 · Cited by 177
Garcia, J. M., Friend, J., & Allen, S. (2013) · Supportive Care in Cancer · doi:10.1007/s00520-012-1500-1 · Cited by 169
Insulin Treatment in Cancer Cachexia: Effects on Survival, Metabolism, and Physical Functioning
Lundholm, K., Körner, U., Gunnebo, L., Sixt-Ammilon, P., Fouladiun, M., Daneryd, P., & Bosaeus, I. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2720 · Cited by 143
Takayama, K., Katakami, N., Yokoyama, T., Atagi, S., Yoshimori, K., Kagamu, H., Saito, H., Takiguchi, Y., Aoe, K., Koyama, A., et al. (2016) · Supportive Care in Cancer · doi:10.1007/s00520-016-3144-z · Cited by 141
Pietra, C., Takeda, Y., Tazawa-Ogata, N., Minami, M., Yuanfeng, X., Duus, E. M., & Northrup, R. (2014) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1007/s13539-014-0159-5 · Cited by 114
Role of Corticosteroids in Palliative Care
Shih, A., & Jackson, K. C. (2007) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.1080/j354v21n04_14 · Cited by 109
Garcia, J. M., & Polvino, W. J. (2009) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2008.12.003 · Cited by 89
Nagaya, N., Kojima, M., & Kangawa, K. (2006) · Internal Medicine · doi:10.2169/internalmedicine.45.1402 · Cited by 79
Cancer Cachexia Syndrome: Pathogenesis, Diagnosis, and New Therapeutic Options
Mondello, P., Mian, M., Aloisi, C., Famà, F., Mondello, S., & Pitini, V. V. (2014) · Nutrition and Cancer · doi:10.1080/01635581.2015.976318 · Cited by 73
Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC
Zhang, H., & Garcia, J. M. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1041500 · Cited by 60
Northrup, R., Kuroda, K., Duus, E. M., Barnes, S. R., Cheatham, L., Wiley, T., & Pietra, C. (2013) · Supportive Care in Cancer · doi:10.1007/s00520-013-1800-0 · Cited by 51
Tarricone, R., Ricca, G., Wakholi, B. N., & Medina‐Lara, A. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.12.008 · Cited by 51
The Role of Ghrelin in Anorexia–Cachexia Syndromes
Guillory, B., Splenser, A. E., & Garcia, J. M. (2013) · Vitamins and hormones · doi:10.1016/b978-0-12-410473-0.00003-9 · Cited by 39
Espósito, A., Criscitiello, C., Gelao, L., Pravettoni, G., Locatelli, M., Minchella, I., Leo, M. D., Liuzzi, R., Milani, A., Massaro, M., et al. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.09.002 · Cited by 37
Thalidomide Suppresses the Interleukin 1β‐Induced NFκB Signaling Pathway in Colon Cancer Cells
Jin, S. H., Kim, T. I., Han, D. S., Shin, S. K., & Kim, W. H. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04674.x · Cited by 34
Multitargeted Treatment of Cancer Cachexia
Madeddu, C., Macciò, A., & Mantovani, G. (2012) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v17.i3.80 · Cited by 30
The role of C-terminal part of ghrelin in pharmacokinetic profile and biological activity in rats
Morozumi, N., Hanada, T., Habara, H., Yamaki, A., Furuya, M., Nakatsuka, T., Inomata, N., Minamitake, Y., Ohsuye, K., & Kangawa, K. (2011) · Peptides · doi:10.1016/j.peptides.2011.01.021 · Cited by 26
Leese, P. T., Trang, J. M., Blum, R. A., & de Groot, E. (2014) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.175 · Cited by 17
Long term survivors of childhood brain cancer have an increased risk for cardiovascular disease
(2000) · Pure Amsterdam UMC · doi:10.1002/(sici)1097-0142(20000501)88:9
Research works printed but not linked: 1
- Chang VT, Hwang SS, Feuerman M (2000) Validation of the Edmonton symptom assessment scale. Cancer 88:2164–2171 · doi:10.1002/(sici)1097-0142(20000501)88:9<2164::aid-cncr24>3.0.co;2-5
Cited by
Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies
Batsis, J. A., & Villareal, D. T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0062-9 · Cited by 1,382
Management of Cancer Cachexia: ASCO Guideline
Roeland, E. J., Bohlke, K., Baracos, V. E., Bruera, E., del Fabbro, E., Dixon, S., Fallon, M., Herrstedt, J., Lau, H., Platek, M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00611 · Cited by 644
Bozzetti, F. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx271 · Cited by 323
Inter-tissue communication in cancer cachexia
Argilés, J. M., Stemmler, B., López-Soriano, F. J., & Busquets, S. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0123-0 · Cited by 305
Advani, S., Advani, P. G., VonVille, H. M., & Jafri, S. H. R. (2018) · BMC Cancer · doi:10.1186/s12885-018-5080-4 · Cited by 139
Metadata
- Authors
- Bai, Y., Hu, Y., Zhao, Y., Yu, X., Xu, J., Hua, Z., & Zhao, Z.
- Affiliations
- Nanjing University of Chinese Medicine (CN)
- Corresponding author
- Zhao, Zhiqiang
- Venue
- Supportive Care in Cancer
- Published
- 2017-01-10
- Volume
- 25
- Issue
- 5
- Pages
- 1651-1659
- ISSN
- 0941-4355 (ISSN-L)
- 1433-7339
- OpenAlex
- W2569392536
- Cited by
- 52
- References
- 32
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 2 · 2021: 7 · 2020: 7 · 2019: 6 · 2018: 10 · 2017: 8
- FWCI
- 1.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Supportive Care in Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81373608)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Health Sciences › Nursing › Nutrition and Dietetics › Clinical Nutrition and Gastroenterology
- Social Sciences › Psychology › Clinical Psychology › Eating Disorders and Behaviors
- Keywords
- cancer anorexia-cachexia syndrome, lean body mass, body weight, grip strength, insulin-like growth factor I, IGF binding protein-3, adverse events, quality of life, growth hormone secretagogues, placebo comparison, heterogeneity of results, quality of evidence
- MeSH terms
- Anorexia, Cachexia, Female, Humans, Hydrazines, Neoplasms, Oligopeptides, Quality of Life, Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.